Progress of long-acting interferon in Philadelphia chromosome-negative myloproliferative neoplasms
10.3760/cma.j.cn115356-20220615-00172
- VernacularTitle:长效干扰素在费城染色体阴性骨髓增殖性肿瘤中的研究进展
- Author:
Binbin WANG
1
;
Gusheng TANG
Author Information
1. 海军军医大学第一附属医院血液内科，上海 200433
- Keywords:
Myeloproliferative neoplasms;
Interferon;
Molecular response rate
- From:
Journal of Leukemia & Lymphoma
2023;32(10):628-630
- CountryChina
- Language:Chinese
-
Abstract:
Philadelphia chromosome-negative myeloproliferative neoplasms (MPN) is a group of chronic hematological tumors caused by clonal proliferation of hematopoietic stem cells, and hydroxyurea is the traditional first-line chemotherapy drug for it. In recent years, pegylated interferon has shown great advantages in the clinical treatment of MPN, and it has become the first-line preferred therapeutic regimen for special populations, especially for young patients and pregnant women.
